Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells

Background/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly...

Full description

Bibliographic Details
Main Authors: Peruničić-Jovanović Maja, Jaković Ljubomir, Bogdanović Andrija, Marković Olivera, Čemerikić-Martinović Vesna, Mihaljević Biljana
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2009-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdf
id doaj-ab6aaa9e547e4c6f874fe29afdc3990d
record_format Article
spelling doaj-ab6aaa9e547e4c6f874fe29afdc3990d2020-11-24T23:11:37ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502009-01-0166973874310.2298/VSP0909738PPoor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cellsPeruničić-Jovanović MajaJaković LjubomirBogdanović AndrijaMarković OliveraČemerikić-Martinović VesnaMihaljević BiljanaBackground/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly diagnosed patients with DLBCL, treated with CHOP/R-CHOP (cyclophosphemide doxorubicine, vincristine, prednisone with or without rituximab) regimen, we analyzed the prognostic value of the expression of Ki67 and bcl-2 at diagnosis as well as other standard clinical parameters: International Prognostic Index (IPI), bulky disease, extranodal distribution and lactat dehydrogenase (LDH). Significance was tested according to response rate and overall survival. Results. Univariate survival analysis showed that high IPI had a statistically significant negative influence on overall and event free survival time (log rank, p < 0.01). The log rank test analysis signified that patients with a high proliferative fraction (Ki-67 > 60%) had a worse overall survival rate (OS5y) of 40% compared to those with low proliferation (Ki-67 < 60%) with OS5y of 80% (p < 0.01). There was a clear difference between bcl-2 positivity (treshold 50%) and the achievement of complete remission (66% vs 86% in patients with bcl-2 high and low levels respectively, p < 0.05). In survival analysis, patients with low bcl-2 expression had significantly higher OS5y - 68% compared to those with high bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis performed by Cox model revealed that IPI > 3, high Ki-67+, bcl-2 positivity had a significant independent prognostic value concerning overall survival (p < 0.05). Conclusion. An initial high IPI score associated with high Ki-67+ and bcl2+ could represent possible predictive factors of poor prognosis, which would help to identify a high risk subgroup of newly diagnosed DLBCL.http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdflymphoma, B-cellgenes, bcl-2Ki-67 antigenprognosisantineoplastic combined chemotherapy protocols
collection DOAJ
language English
format Article
sources DOAJ
author Peruničić-Jovanović Maja
Jaković Ljubomir
Bogdanović Andrija
Marković Olivera
Čemerikić-Martinović Vesna
Mihaljević Biljana
spellingShingle Peruničić-Jovanović Maja
Jaković Ljubomir
Bogdanović Andrija
Marković Olivera
Čemerikić-Martinović Vesna
Mihaljević Biljana
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
Vojnosanitetski Pregled
lymphoma, B-cell
genes, bcl-2
Ki-67 antigen
prognosis
antineoplastic combined chemotherapy protocols
author_facet Peruničić-Jovanović Maja
Jaković Ljubomir
Bogdanović Andrija
Marković Olivera
Čemerikić-Martinović Vesna
Mihaljević Biljana
author_sort Peruničić-Jovanović Maja
title Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
title_short Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
title_full Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
title_fullStr Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
title_full_unstemmed Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
title_sort poor outcome in patients with diffuse large b-cell lymphoma is associated with high percentage of bcl-2 and ki 67-positive tumor cells
publisher Military Health Department, Ministry of Defance, Serbia
series Vojnosanitetski Pregled
issn 0042-8450
publishDate 2009-01-01
description Background/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly diagnosed patients with DLBCL, treated with CHOP/R-CHOP (cyclophosphemide doxorubicine, vincristine, prednisone with or without rituximab) regimen, we analyzed the prognostic value of the expression of Ki67 and bcl-2 at diagnosis as well as other standard clinical parameters: International Prognostic Index (IPI), bulky disease, extranodal distribution and lactat dehydrogenase (LDH). Significance was tested according to response rate and overall survival. Results. Univariate survival analysis showed that high IPI had a statistically significant negative influence on overall and event free survival time (log rank, p < 0.01). The log rank test analysis signified that patients with a high proliferative fraction (Ki-67 > 60%) had a worse overall survival rate (OS5y) of 40% compared to those with low proliferation (Ki-67 < 60%) with OS5y of 80% (p < 0.01). There was a clear difference between bcl-2 positivity (treshold 50%) and the achievement of complete remission (66% vs 86% in patients with bcl-2 high and low levels respectively, p < 0.05). In survival analysis, patients with low bcl-2 expression had significantly higher OS5y - 68% compared to those with high bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis performed by Cox model revealed that IPI > 3, high Ki-67+, bcl-2 positivity had a significant independent prognostic value concerning overall survival (p < 0.05). Conclusion. An initial high IPI score associated with high Ki-67+ and bcl2+ could represent possible predictive factors of poor prognosis, which would help to identify a high risk subgroup of newly diagnosed DLBCL.
topic lymphoma, B-cell
genes, bcl-2
Ki-67 antigen
prognosis
antineoplastic combined chemotherapy protocols
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdf
work_keys_str_mv AT perunicicjovanovicmaja pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
AT jakovicljubomir pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
AT bogdanovicandrija pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
AT markovicolivera pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
AT cemerikicmartinovicvesna pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
AT mihaljevicbiljana pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells
_version_ 1725603620560306176